GOT (Glycemia Optimization
Treatment), will examine whether varying dosing regimens of insulin in
combination with oral agents will help patients with type 2 diabetes meet the
AACE goal of an A1c of less than 6.5%
Insulin therapy can effectively
help patients with diabetes achieve tight blood sugar control, defined by the
American Diabetes Association (ADA) as an A1C<7.0%, however, many physicians
delay or inadequately dose insulin for fear that such tight control could
possibly lead to hypoglycemia (low blood sugar).
Aventis Pharmaceuticals
announced the launch of this second large-scale clinical study to help determine
optimum dosing regimens of LantusÒ (insulin glargine [rDNA origin]
injection) in combination with oral medications.
“The GOT trial is an important
step in improving physician understanding of how intensive treatment strategies
are possible and can achieve tight control while at the same time observing the
circumstances that lead to hypoglycemic events,” said investigator Ariel Zisman,
MD, Assistant Professor of Medicine, University of Miami School of Medicine.
“Despite the availability of effective treatments today, achieving tight control
without inducing hypoglycemia remains a somewhat elusive goal in primary care.
The GOT study will help determine whether these events are related to the
treatment regimen or to circumstances that, when addressed with education, may
be reversible.”
Hypoglycemic events are often
linked to events such as skipping a meal, unusually strenuous exercise,
sickness, or other events suggesting that educating patients on the proper use
of insulin and monitoring and follow-up communications with patients may help
reduce the number and severity of these events.
“Although tight glycemic
control is achievable, less than half of the more than 11 million Americans
diagnosed with diabetes are meeting the blood sugar goals established by
clinical guidelines, including an A1C <7%,” said Michael Pfeifer, M.D., medical
product leader at Aventis Pharmaceuticals.
According to a new study by the
U.S. Department of Health and Human Services, the nation now spends $13,243 on
each person with diabetes, compared to $2,560 for people without the disease.
This represents a direct medical cost of $91.8 billion.
In making the announcement, Francine R. Kaufman, M.D., president of the
American Diabetes Association called on the nation to “eliminate or reduce the
health problems caused by diabetes through more intensive disease management and
use of new medical technologies and treatments.”
The GOT trial is a U.S.-based, prospective, open-label trial, involving more than 6,000 type 2 diabetes patients in the U.S. from about 1,200 primary care physicians’ offices. A previous study has shown that 57% of patients treated with LantusÒ reached the A1C target of less than 7.0% with a low incidence of hypoglycemic events.
Source: Diabetes In Control Dot Com.
Home - Table of Contents - Donate Now - About Diabetes - Warning Signs - Complications - Screening Test - Diabetes Terms - Site Search - Meet Mr. Diabetes® - Wake Up And Walk® Tour - Latest News - Headlines & News Stories - Health & Fitness - About Us - FAQ - Research Form - - Message Board - Privacy Policy - Legal Notices - How to Contact Us - Comments form - Suggestion Form - Our E-Mail Addresses - Our Address and Phone Numbers - Links - Contact Us